Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis

ilustraciones, gráficas, tablas

Autores:
Burgos Cárdenas, Álvaro Javier
Tipo de recurso:
Fecha de publicación:
2021
Institución:
Universidad Nacional de Colombia
Repositorio:
Universidad Nacional de Colombia
Idioma:
spa
OAI Identifier:
oai:repositorio.unal.edu.co:unal/81060
Acceso en línea:
https://repositorio.unal.edu.co/handle/unal/81060
https://repositorio.unal.edu.co/
Palabra clave:
610 - Medicina y salud
Interferon-alpha
Hepatitis B
Antigens
Interferón-alfa
Hepatitis B
Antígenos
Hepatitis B Crónica
Pronóstico
Interferón
Chronic Hepatitis B
Prognosis
Interferon
Chronic Hepatitis B
Prognosis
Interferon
Rights
openAccess
License
Reconocimiento 4.0 Internacional
id UNACIONAL2_201ae3d12a79edbd8ee4a288cec733ef
oai_identifier_str oai:repositorio.unal.edu.co:unal/81060
network_acronym_str UNACIONAL2
network_name_str Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
dc.title.translated.eng.fl_str_mv Evaluation of viral antigens as prognostic factors of response to treatment with interferon alpha in patients with Chronic Hepatitis B: Systematic review and meta-analysis
title Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
spellingShingle Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
610 - Medicina y salud
Interferon-alpha
Hepatitis B
Antigens
Interferón-alfa
Hepatitis B
Antígenos
Hepatitis B Crónica
Pronóstico
Interferón
Chronic Hepatitis B
Prognosis
Interferon
Chronic Hepatitis B
Prognosis
Interferon
title_short Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
title_full Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
title_fullStr Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
title_full_unstemmed Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
title_sort Evaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisis
dc.creator.fl_str_mv Burgos Cárdenas, Álvaro Javier
dc.contributor.advisor.spa.fl_str_mv Grillo Ardila, Carlos Fernando
dc.contributor.author.spa.fl_str_mv Burgos Cárdenas, Álvaro Javier
dc.subject.ddc.spa.fl_str_mv 610 - Medicina y salud
topic 610 - Medicina y salud
Interferon-alpha
Hepatitis B
Antigens
Interferón-alfa
Hepatitis B
Antígenos
Hepatitis B Crónica
Pronóstico
Interferón
Chronic Hepatitis B
Prognosis
Interferon
Chronic Hepatitis B
Prognosis
Interferon
dc.subject.decs.eng.fl_str_mv Interferon-alpha
Hepatitis B
Antigens
dc.subject.decs.spa.fl_str_mv Interferón-alfa
Hepatitis B
Antígenos
dc.subject.proposal.spa.fl_str_mv Hepatitis B Crónica
Pronóstico
Interferón
dc.subject.proposal.eng.fl_str_mv Chronic Hepatitis B
Prognosis
Interferon
Chronic Hepatitis B
Prognosis
Interferon
description ilustraciones, gráficas, tablas
publishDate 2021
dc.date.issued.none.fl_str_mv 2021
dc.date.accessioned.none.fl_str_mv 2022-02-25T16:24:03Z
dc.date.available.none.fl_str_mv 2022-02-25T16:24:03Z
dc.type.spa.fl_str_mv Trabajo de grado - Maestría
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.content.spa.fl_str_mv Text
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/TM
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unal.edu.co/handle/unal/81060
dc.identifier.instname.spa.fl_str_mv Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv https://repositorio.unal.edu.co/
url https://repositorio.unal.edu.co/handle/unal/81060
https://repositorio.unal.edu.co/
identifier_str_mv Universidad Nacional de Colombia
Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.indexed.spa.fl_str_mv Bireme
dc.relation.references.spa.fl_str_mv 1. World Health Organization 2017. Global Hepatitis Report 2017. 2017.
2. Schmit N, Nayagam S, Thursz MR, Hallett TB. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. Int J Epidemiol. 2021;50(2):560–9.
3. OMS | Hepatitis B [Internet]. World Health Organization; [cited 2015 Mar 21]. Available from: http://www.who.int/mediacentre/factsheets/fs204/es/
4. Dienstag JL. 46 – Antiviral Drugs against Hepatitis Viruses. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases [Internet]. 2015. p. 563-575.e3. Available from:
5. Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: Systematic review and meta-analysis. J Viral Hepat. 2016;23(3):154–69.
6. Likhitsup A, Lok AS. Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials. Clin Liver Dis [Internet]. 2019;23(3):401–16. Available from:
7. Hu J. Hepatitis B Virus Virology and Replication. In: Hepatitis B Virus in Human Diseases [Internet]. 2016. p. 1–34. Available from: http://link.springer.com/10.1007/978-3-319-22330-8_1
8. European Association for the Study of the Liver (EASL). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol [Internet]. 2017;67(2):370–98. Available from: http://www.easl.eu/medias/cpg/management-of-hepatitis-B-virus-infection/English-report.pdf
9. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis b. J Antimicrob Chemother. 2011;66(12):2715–25.
10. Liaw Y-F, Kao J-H, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int [Internet]. 2012;6(3):531–61. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L52014826&from=export
11. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.
12. Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, et al. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. Can Liver J. 2018;1(4):156–217
13. Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, et al. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc [Internet]. 2019;118(1P1):7–38. Available from: https://doi.org/10.1016/j.jfma.2018.11.008
14. Ministerio de Salud y Protección Social; Instituto de Evaluación Tecnológica en Salud. Guía de Práctica Clínica Diagnóstico y Tratamiento de Hepatitis B crónica Adopción Sistema General de Seguridad Social en Salud Colombia. 2016;(56):1–287.
15. Chan HL-Y, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. J Hepatol [Internet]. 2011;55(5):1121–31. Available from:
16. Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol [Internet]. 2019;16(10):631–41. Available from: http://dx.doi.org/10.1038/s41575-019-0197-8
17. Wu JW, Kao JH, Tseng TC. Three heads are better than two: Hepatitis b core-related antigen as a new predictor of hepatitis b virus-related hepatocellular carcinoma. Clin Mol Hepatol. 2021;27(3).
18. Chan HL, Wong VW, Tse AM, Tse C, Chim AM, Chan H, et al. Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. Clin Gastroenterol Hepatol [Internet]. 2007;5(12):1462–8. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L350181604&from=export
19. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int [Internet]. 2014 Feb 1 [cited 2015 Jan 27];34 Suppl 1(s1):97–107. Available from: http://aplicacionesbiblioteca.udea.edu.co:2144/doi/10.1111/liv.12403/full
20. Mak L-Y, Seto W-K, Fung J, Yuen M-F. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int [Internet]. 2020;14(1):35–46. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2003652617&from=export
21. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology. 2009;49(SUPPL. 5).
22. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection. Jama [Internet]. 2018;319(17):1802. Available from:
23. World Health Organization 2016. GLOBAL HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS 2016-2021 TOWARDS ENDING VIRAL HEPAITITS. 2016;
24. Chan HLY, Ahn SH, Chang T-T, Peng C-Y, Wong D, Coffin CS, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J Hepatol [Internet]. 2016;64(5):1011–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L608677780&from=export
25. Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Prim [Internet]. 2018;4:1–21. Available from: http://dx.doi.org/10.1038/nrdp.2018.35
26. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol. 2003;39(SUPPL. 1):26–30.
27. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000 May;15 Suppl:E25-30.
28. Wong GLH, Wong VWS, Chan HLY. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis. 2016;62(Suppl 4):S298–305.
29. Vlachogiannakos J, Papatheodoridis G V. Optimal therapy of chronic hepatitis B: How do I treat HBeAg-positive patients? Liver Int [Internet]. 2015;35(s1):100–6. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L601030651&from=export
30. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 SUPPL. 1).
31. Dienstag JL, Delemos AS. 119 – Viral Hepatitis. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases [Internet]. 2015. p. 1439-1468.e7. Available from: http://www.sciencedirect.com/science/article/pii/B9781455748013001193
32. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012;61(SUPPL. 1).
33. Liu C-J, Kao J-H. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013 May;33(2):97–102.
34. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000 Jan;81(Pt 1):67–74.
35. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000 Mar;118(3):554–9.
36. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology [Internet]. 2003 Jan 1;37(1):19–26. Available from: https://doi.org/10.1053/jhep.2003.50036
37. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002 Dec;123(6):1848–56.
38. Revill PA, Chisari F V., Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545–58.
39. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–66.
40. Fitzmaurice C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91.
41. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J [Internet]. 2016 Jul 14;37(27):2129–200. Available from: http://doi.wiley.com/10.1016/j.ejheart.2008.08.005
42. Yang H-I, Lu S-N, Liaw Y-F, You S-L, Sun C-A, Wang L-Y, et al. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. N Engl J Med [Internet]. 2002;347(3):168–74. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa013215
43. Lin S-M, Sheen I-S, Chien R-N, Chu C-M, Liaw Y-F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology [Internet]. 1999 Mar;29(3):971–5. Available from: http://doi.wiley.com/10.1002/hep.510290312
44. Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol [Internet]. 2013;57(4):323–30. Available from: http://dx.doi.org/10.1016/j.jcv.2013.04.012
45. Lauret E, González-Diéguez ML, Rodríguez M, González M, Melón S, Rodrigo L, et al. Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance. Liver Int. 2015;35(1):140–7.
46. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—Summary of a workshop. Gastroenterology [Internet]. 2001;120(7):1828–53. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508501701904
47. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of hepatitis B: Summary of a clinical research workshop. Hepatology. 2007;45(4):1056–75.
48. Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, et al. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization. Cancer [Internet]. 2007 Oct 15;110(8):1760–7. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cncr.22984
49. Konerman MA, Lok AS. Interferon Treatment for Hepatitis B. Clin Liver Dis [Internet]. 2016 Nov;20(4):645–65. Available from: http://dx.doi.org/10.1016/j.cld.2016.06.002
50. Samuel CE. Antiviral Actions of Interferons. Clin Microbiol Rev [Internet]. 2001 Oct 1;14(4):778–809. Available from: http://cmr.asm.org/cgi/doi/10.1128/CMR.14.4.778-809.2001
51. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN- α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. 2012;122(2).
52. Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky J-M. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013 Apr;58(4):676–83.
53. Wong D, Cheung A, O’Rourke K, Naylor C, Detsky A, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119(4):312–23.
54. Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, et al. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol [Internet]. 2018 Mar 28;6(1):1–10. Available from: http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=1&id=10.14218%2FJCTH.2017.00073
55. Seo Y. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol [Internet]. 2014;20(37):13284. Available from: http://www.wjgnet.com/1007-9327/full/v20/i37/13284.htm
56. Janssen H LA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet [Internet]. 2005 Jan;365(9454):123–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673605177010
57. Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, et al. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc [Internet]. 2018;117(7):588–97. Available from: https://doi.org/10.1016/j.jfma.2017.12.007
58. Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersöz G, et al. Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007;51(8):3020–2.
59. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology [Internet]. 2009 May;49(S5):S103–11. Available from: http://doi.wiley.com/10.1002/hep.22956
60. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: Characteristics and vulnerability. J Psychosom Res [Internet]. 2007 Aug;63(2):131–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022399907002164
61. Peng H, Wei F, Liu JY, Hu HD, Ren H, Hu P. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. Hepatol Int. 2015;9(4):543–57.
62. Chan HL-Y, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol [Internet]. 2011 Nov 11 [cited 2015 Jan 25];55(5):1121–31. Available from: http://www.journal-of-hepatology.eu/article/S0168827811004971/fulltext
63. Lo AO-S, Wong VW-S, Wong GL-H, Chan HL-Y, Dan Y-Y. Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. Clin Gastroenterol Hepatol [Internet]. 2015 Feb [cited 2015 Aug 25];13(2):377-385.e5. Available from: http://www.sciencedirect.com/science/article/pii/S154235651400929X
64. Liu T, Zhu G, He J, Song T, Zhang M, Lin H, et al. Early rigorous control interventions can largely reduce dengue outbreak magnitude: Experience from Chaozhou, China. BMC Public Health. 2017;18(1):1–10.
65. Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, et al. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virol J [Internet]. 2016;13(1):1–9. Available from: http://dx.doi.org/10.1186/s12985-016-0640-1
66. Perrillo R, Hou J, Papatheodoridis G, Manns M. Patient management and clinical decision making in HBV - Aims of therapy and what we can achieve. Antivir Ther. 2010;15(SUPPL. 3):45–51.
67. Hsu HY, Tsai HY, Wu TC, Chiang CL, Ni YH, Chen PJ, et al. Interferon-α treatment in children and young adults with chronic hepatitis B: A long-term follow-up study in Taiwan. Liver Int. 2008;28(9):1288–97.
68. Wiegand J, van Bommel F, Berg T. Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis. 2010;1(212):361–77.
69. Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, et al. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2016;44(9):957–66.
70. Hadziyannis E, Hadziyannis SJ. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility. Expert Rev Gastroenterol Hepatol [Internet]. 2014;8:185–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24417264
71. Chien R-N, Kao J-H, Peng C-Y, Chen C-H, Liu C-J, Huang Y-H, et al. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc [Internet]. 2019;118(1P1):7–38. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2001356312&from=export
72. Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. An overview of hepatitis B virus surface antigen secretion inhibitors. Front Microbiol. 2018;9(APR):1–9.
73. Ju H, Lai G, Yan F. 6 - Electrochemiluminescent immunosensing. In: Ju H, Lai G, Yan F, editors. Immunosensing for Detection of Protein Biomarkers [Internet]. Elsevier; 2017. p. 171–206. Available from: https://www.sciencedirect.com/science/article/pii/B9780081019993000062
74. Schnurr B, Ahrens T, Regenass U. Optical assays in drug discovery. Compr Med Chem II. 2006;3:577–98.
75. Paul-Ehrlich-Institut. PEI Sero­log­i­cal Ref­er­ence Ma­te­ri­al [Internet]. 2021. Available from: https://www.pei.de/EN/regulation/reference-material/reference-material-node.html
76. Karagoz E, Selek MB, Tanoglu A, Hatipoglu M, Ulçay A, Turhan V. Comparison of the Elecsys HBsAg II assay and the Architect assay for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. Infez Med. 2016;24(4):287–92.
77. van Halewijn GJ, Geurtsvankessel CH, Klaasse J, van Oord GW, de Knegt RJ, van Campenhout MJ, et al. Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. J Clin Virol [Internet]. 2019;114(February 2019):1–5. Available from: https://doi.org/10.1016/j.jcv.2019.03.003
78. Thio CL, Hawkins C. 148 – Hepatitis B Virus and Hepatitis Delta Virus. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases [Internet]. 2015. p. 1815-1839.e7. Available from: http://www.sciencedirect.com/science/article/pii/B978145574801300148X
79. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife [Internet]. 2012 Nov 13 [cited 2015 Jan 4];1:e00049. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3485615&tool=pmcentrez&rendertype=abstract
80. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology [Internet]. 2015 Mar 7 [cited 2015 Mar 12]; Available from: http://www.sciencedirect.com/science/article/pii/S004268221500077X
81. Rodríguez-Frias F, Jardi R. Virología molecular del virus de la hepatitis B. Enferm Infecc Microbiol Clin [Internet]. 2008;26:2–10. Available from: http://dx.doi.org/10.1016/S0213-005X(08)76514-5
82. Sung JJY, Wong M-L, Bowden S, Liew C-T, Hui AY, Wong VWS, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology [Internet]. 2005;128(7):1890–7. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L40824700&from=export
83. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: New trick of old dog. J Gastroenterol. 2013;48(1):13–21.
84. Altinbas A, Aktaş B, Basar Ö, Yüksel O, Ekiz F, Yilmaz B, et al. Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection? Ann Hepatol. 2012;11(3):320–5.
85. Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology [Internet]. 2009;49(4):1141–50. Available from: http://doi.wiley.com/10.1002/hep.22760
86. Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int. 2015;35(5):1540–8.
87. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study. J Hepatol. 2009;50(6):1084–92.
88. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49(4):1151–7.
89. Janssen HLA, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut [Internet]. 2012;61(5):641–5. Available from: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2011-301096
90. Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int. 2016;36(6):827–36.
91. Nguyen T, Thompson AJ V, Bowden S, Croagh C, Bell S, Desmond P V., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. J Hepatol [Internet]. 2010;52(4):508–13. Available from: http://dx.doi.org/10.1016/j.jhep.2010.01.007
92. Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol. 2010;25(9):1498–506.
93. Wang M-L, Liao J, Wei B, Zhang D-M, He M, Tao M-C, et al. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy. Infect Dis (Auckl) [Internet]. 2018 Jul 3;50(7):522–30. Available from: https://doi.org/10.1080/23744235.2018.1442018
94. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364.
95. Wilczynski NL, Haynes RB, Eady A, Haynes B, Marks S, McKibbon A, et al. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: An analytic survey. BMC Med. 2004;2:1–5.
96. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. PLoS Med. 2014;11(10).
97. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427–37.
98. Harrer, M., Cuijpers, P., Furukawa, T.A., & Ebert D. Doing Meta-Analysis with R: A Hands-On Guide. 1st ed. Boca Raton, FL: London: Chapmann & Hall/CRC Press; 2021.
99. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: Adapting the GRADE framework. Syst Rev [Internet]. 2013;2(1):1. Available from: Systematic Reviews
100. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52(2):454–61.
101. Chan HLY, Wong VWS, Chim AML, Chan HY, Wong GLH, Sung JJY. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32(11–12):1323–31.
102. Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. J Viral Hepat. 2016;23(6):427–38.
103. Liaw Y-F, Jia J-D, Chan HLY, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology [Internet]. 2011;54(5):1591–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L51655108&from=export
104. Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol [Internet]. 2012;56(5):1006–11. Available from: http://dx.doi.org/10.1016/j.jhep.2011.12.007
105. Piratvisuth T, Marcellin P, Popescu M, Kapprell H-P, Rothe V, Lu Z-M. Hepatitis B surface antigen: Association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int [Internet]. 2013;7(2):429–36. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L51491678&from=export
106. Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int [Internet]. 2020;14(2):212–24. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2004342428&from=export
107. Zhang C, Yang Z, Wang Z, Dou X, Sheng Q, Li Y, et al. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int J Med Sci [Internet]. 2020;17(3):383–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L631162849&from=export
108. Marcellin P, Xie Q, Paik SW, Flisiak R, Piratvisuth T, Petersen J, et al. Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS One [Internet]. 2020;15(4). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2005559394&from=export
109. Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, et al. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients. World J Gastroenterol. 2015;21(18):5668–76.
110. Zhu X, Gong Q, Yu D, Zhang D, Gu L, Han Y, et al. Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. J Clin Virol [Internet]. 2013;57(4):318–22. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L52558617&from=export
111. Peng C-Y, Lai H-C, Li Y-F, Su W-P, Chuang P-H, Kao J-T. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther [Internet]. 2012;35(4):458–68. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L51807413&from=export
112. Lee I-C, Su C-W, Lan K-H, Wang Y-J, Lee K-C, Lin H-C, et al. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc [Internet]. 2020; Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2010380121&from=export
113. Lee IC, Huang YH, Su CW, Wang YJ, Huo TI, Lee KC, et al. CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study. PLoS One. 2013;8(10):1–11.
114. Li H, Wang H, Peng C, Zheng X, Liu J, Weng Z, et al. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B. J Huazhong Univ Sci Technol [Medical Sci [Internet]. 2017 Aug 8;37(4):547–55. Available from: http://link.springer.com/10.1007/s11596-017-1771-3
115. Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int. 2015;35(5):1540–8.
116. Ma H, Yang R-F, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol [Internet]. 2010;25(9):1498–506. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L359429499&from=export
117. Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol [Internet]. 2021;74(2):283–92. Available from: https://doi.org/10.1016/j.jhep.2020.08.039
118. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-??-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res. 2010;40(3):269–77.
119. Zhu M-Y, Chen P-Z, Li J, Yu D-M, Huang D, Zhu X-J, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol [Internet]. 2018 Apr;90(4):721–9. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.25010
120. Jia W, Zhu MQ, Qi X, Wang T, Wen X, Chen PD, et al. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J [Internet]. 2019;16(1). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L627530822&from=export
121. Boglione L, Cusato J, Cariti G, Di Perri G, D’Avolio A. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. Antiviral Res [Internet]. 2016;136:32–6. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L612977889&from=export
122. Gheorghiţǎ VI, Cǎruntu FA, Curescu M, Olaru I, Radu MN, Colţan G, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: A Romanian cohort study. J Gastrointest Liver Dis. 2013;22(1):27–32.
123. Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T, Thongsawat S, Sanpajit T, Chonprasertsuk S, et al. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol [Internet]. 2016;31(11):1874–81. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L613365032&from=export
124. Chen J, Xu CR, Xi M, Hu WW, Tang ZH, Zang GQ. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels. J Viral Hepat [Internet]. 2017;24(7):573–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L614521674&from=export
125. Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience. Clin Ther [Internet]. 2021;43(3):572-581.e3. Available from: https://doi.org/10.1016/j.clinthera.2020.12.022
126. Zhu MY, Chen PZ, Li J, Yu DM, Huang D, Zhu XJ, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol. 2018;90(4):721–9.
127. Chuaypen N, Posuwan N, Chittmittraprap S, Hirankarn N, Treeprasertsuk S, Tanaka Y, et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon–based therapy. Clin Microbiol Infect [Internet]. 2018;24(3):306.e7-306.e13. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L618234108&from=export
128. Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. J Viral Hepat [Internet]. 2016;23(6):427–38. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L606643615&from=export
129. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology [Internet]. 2010;52(2):454–61. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L359366376&from=export
130. Moucari R, Mackiewicz V, Lada O, Ripault M-P, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology [Internet]. 2009;49(4):1151–7. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L354752655&from=export
131. Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int [Internet]. 2015;35(5):1540–8. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L603807797&from=export
132. Gheorghiţǎ VI, Cǎruntu FA, Curescu M, Olaru I, Radu MN, Colţan G, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: A Romanian cohort study. J Gastrointest Liver Dis [Internet]. 2013;22(1):27–32. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L368602002&from=export
133. Chan HLY, Wong VWS, Chim a. ML, Chan HY, Wong GLH, Sung JJY. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32(11–12):1323–31.
134. Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int [Internet]. 2016;36(6):827–36. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L610369463&from=export
135. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res [Internet]. 2010;40(3):269–77. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L359134396&from=export
136. Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, et al. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virol J [Internet]. 2016;13(1):1–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L612941879&from=export
137. Zhu M-Y, Chen P-Z, Li J, Yu D-M, Huang D, Zhu X-J, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol [Internet]. 2018;90(4):721–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L620282188&from=export
138. Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T, Thongsawat S, Sanpajit T, Chonprasertsuk S, et al. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol. 2016;31(11):1874–81.
139. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology [Internet]. 2011;53(3):1054–5. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L361365510&from=export
140. Wong GLH, Chan HLY. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69(16):2167–77.
141. Inoue T, Tanaka Y. The role of hepatitis B core-related antigen. Genes (Basel). 2019;10(5).
142. Mak L-Y, Wong DK-H, Cheung K-S, Seto W-K, Lai C-L, Yuen M-F. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther [Internet]. 2018;47(1):43–54. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L618799527&from=export
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Reconocimiento 4.0 Internacional
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Reconocimiento 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv xx, 137 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv Bogotá - Medicina - Maestría en Epidemiología Clínica
dc.publisher.faculty.spa.fl_str_mv Facultad de Medicina
dc.publisher.place.spa.fl_str_mv Bogotá, Colombia
dc.publisher.branch.spa.fl_str_mv Universidad Nacional de Colombia - Sede Bogotá
institution Universidad Nacional de Colombia
bitstream.url.fl_str_mv https://repositorio.unal.edu.co/bitstream/unal/81060/3/1085277852%202021%20.pdf
https://repositorio.unal.edu.co/bitstream/unal/81060/4/license.txt
https://repositorio.unal.edu.co/bitstream/unal/81060/5/1085277852%202021%20.pdf.jpg
bitstream.checksum.fl_str_mv 98928ae75cd540e500327f6018456727
8153f7789df02f0a4c9e079953658ab2
045623136e4d62c9754f826196aafe8b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv repositorio_nal@unal.edu.co
_version_ 1814089358877130752
spelling Reconocimiento 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Grillo Ardila, Carlos Fernando30b10dd10df75301c7b60a994a61d9f6Burgos Cárdenas, Álvaro Javier3ad010cec8ed5c40003bb9ee2480a6092022-02-25T16:24:03Z2022-02-25T16:24:03Z2021https://repositorio.unal.edu.co/handle/unal/81060Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, gráficas, tablasEl interferón alfa y los análogos de nucleótidos son los pilares del tratamiento para la Hepatitis B Crónica ; los análogos de nucleótidos son los más usados debido a una menor tasa de eventos adversos, en comparación al Interferón. Sin embargo, no son capaces de eliminar el virus de las células infectadas, la tasa de control serológico es menor y la duración del tratamiento es indefinida. Por lo mencionado, se hace necesarios factores pronósticos para determinar, en la medida de los posible, a los pacientes que tengan mayor chance de responder a la terapia con Interferón. Actualmente, las concentraciones séricas de los antígenos o proteínas virales, tal es como el antígeno de superficie(HBsAg), antígeno e (HBeAg) y la proteína relacionada con el core (HBcrAg), parecen ser factores pronósticos prometedores. Por anterior, se realizó una revisión sistemática con metanálisis para evaluar la asociación entre la concentración del HBsAg, HBeAg y HBcrAg medidos a la semana 12 y una respuesta favorable al terminar tratamiento con interferón . Metodología: Se realizó una búsqueda sistemática de la literatura, en MEDLINE, EMBASE, y CENTRAL de Cochrane, y otras fuentes de información, como páginas de sociedades científicas y revistas relacionadas con el tema; literatura gris y congresos internacionales. Se seleccionaron los artículos que evaluaran la asociación de la concentración sérica de HBsAg, HBeAg y HBcrAg a la semana 12 de tratamiento con interferón y la respuesta al final del tratamiento. Los factores pronósticos, en este caso las concentraciones de los antígeno virales, fueron dicotomizados para el análisis de la siguiente manera: se considero como presente el factor pronóstico cuando un individuo tenia concentraciones de estas partículas a la semana 12 por debajo de un punto de corte establecido, de la misma manera, el factor se encontraba presente cuando el delta de la concentración del antígeno, entre la semana 0 y la semana 12 de tratamiento, se encontraba por encima de un umbral establecido por los autores del estudio. Dichos puntos de corte o umbrales fueron determinadas por los autores de cada estudio y se determino su asociación con la respuesta al tratamiento, de acuerdo con la frecuencia de respuesta serológica, viral o combinadas obtenidas entre los individuos con y sin el factor pronóstico, al menos al término del tratamiento. Resultados: 31(5.167 participantes) estudios cumplieron los criterios de inclusión. La certeza de la evidencia sobre la concentración del HBsAg a la semana 12 como factor pronóstico fue calificada como de muy baja calidad, de acuerdo a la metodología GRADE por lo que existe incertidumbre sobre si existe asociación entre el factor y el desenlace, sea que se analice como una concentración absoluta por debajo de un punto de corte o el delta entre la semana 0 y 12 (Delta para eliminación del HBsAg: OR: 6.02, IC95%: 3.76-9.65 tau2: 0 I2. 0.0%| Concentración absoluta eliminación del HBsAg: OR: 5.490, IC95%: 2.7925-10.793 tau2: 0 I2. 0.0% ) (Delta para la seroconversión del HBeAg: OR: 5.39 IC95%:2.55-11.41| Concentración absoluta para la seroconversión del HBeAg: OR 3.12 IC95%: 2.15-4.52, tau2:0.116, I2: 47% ). Con respecto a la evaluación como factor pronóstico de la concentración del HBeAg medido a la semana 12 de tratamiento con interferón, se encontró que la certeza de la evidencia era de muy baja calidad, por lo que se determino que existe incertidumbre en cuanto a si tener una disminución entre la semana 0 y 12 por encima de un umbral establecido o una concentración por debajo del punto de corte del HBeAg, se asocien con una mayor posibilidad del obtener la eliminación del HBsAg o seroconversión del HBeAg al menos al terminar el tratamiento (Delta para eliminación del HBsAg OR:7.27 IC95%:2.0-26.411|Concentración absoluta para seroconversión del HBeAg: OR ajustado(carga viral, ALT, edad): 10.89 IC95% : 2.63-45.17 ). Para el HBcrAg, con evidencia de muy baja calidad, no se puede determinar si la disminución de este antígeno entre la semana 0 y 12 no se asocia con la eliminación del HBsAg (OR: 2.76 IC95%: 0.85-8.9). En relación con los desenlaces secundarios, con muy baja calidad de la evidencia, no se puede establecer si la disminución entre la semana 0 y 12 o una concentración por debajo del punto de corte de los tres factores pronósticos, se asoció con una respuesta viral o combinada. Conclusiones: Los resultados de esta revisión muestran que no existe certeza sobre la asociación entre los factores pronósticos aquí estudiados y la respuesta al tratamiento ya que la evidencia fue de muy baja calidad y no se puede concluir que en pacientes con Hepatitis b Crónica tratados con Interferón alfa, la medición en sangre de la concentración del HBsAg a la semana 12 después de iniciado el tratamiento, pueda predecir la respuesta al tratamiento, cuando esta respuesta es medida como serológica, viral o combinada. Para mejorar la calidad de la evidencia, hacen falta ensayos clínicos en los que se asigne aleatoriamente a los participantes en función del factor pronósticos a modificar el tratamiento o continuar con el. Asimismo, se podrían realizar mejores análisis multivariados o estudios pronósticos en los que haya mejor control de la confusión. (Texto tomado de la fuente).Alpha interferon and nucleotide analogs are the mainstays of treatment for Chronic Hepatitis B; Nucleotide analogs are the most used due to a lower rate of adverse events than interferon. However, they cannot eliminate the virus from infected cells, their serological control rate is lower than interferon, and the duration of treatment is indefinite. Due to the above, prognostic factors are necessary to determine, as far as possible, the patients who are most likely to respond to Interferon therapy. Currently, serum concentrations of viral proteins or ends, such as surface end (HBsAg), e-end (HBeAg), and core-associated protein (HBcrAg), appear to be promising prognostic factors. Previously, a systematic review with meta-analysis was performed to assess the association between HBsAg, HBeAg, and HBcrAg concentration measured at week 12 and a favorable response at the end of interferon treatment. Methodology: We performed a systematic search of the literature in MEDLINE, EMBASE, and Cochrane CENTRAL, and other sources of information, such as pages of scientific societies and journals related to the subject, like gray literature and international conferences. We selected articles that evaluated the association of the serum concentration of HBsAg, HBeAg, and HBcrAg at week 12 of treatment with interferon and the response at the end of treatment. The prognostic factors, in this case, the concentrations of viral antigens, were dichotomized for the analysis as follows: we considered the prognostic factor present when an individual had concentrations of these particles at week 12 below a cut-off point. In the same way, the factor was present when the delta of the antigen concentration, between week 0 and week 12 of treatment, was above a threshold established by the study authors. The authors of each study determined these cut-off points or thresholds, and we established their association with the response to treatment according to the frequency of serological, viral, or combined response obtained between individuals with and without the prognostic factor, at least at the end of treatment. Results: 31 (5,167 participants) studies met the inclusion criteria. We classified the certainty of the evidence on the concentration of HBsAg at week 12 as a prognostic factor as very low quality, according to the GRADE methodology. For that reason, we considered there is uncertainty about an association between the factor and the outcome, it does not matter how is analyzed as an absolute concentration below a cut-off point or the delta between week 0 and 12 (Delta for HBsAg clearance: OR: 6.02, 95% CI: 3.76-9.65 tau2: 0 I2. 0.0%| Absolute concentration clearance of HBsAg: OR: 5.490, 95% CI: 2.7925-10.793 tau2: 0 I2. 0.0% ) (Delta for HBeAg seroconversion: OR: 5.39 95% CI: 2.55-11.41 | Absolute concentration for HBeAg seroconversion: OR 3.12 95% CI : 2.15-4.52, tau2:0.116, I2: 47% ). Regarding the evaluation as a prognostic factor of the concentration of HBeAg measured at week 12 of treatment with interferon, we found that the certainty of the evidence was of very low quality. Therefore, we determined that there is uncertainty as to whether having a decrease between week 0 and 12 above an established threshold or a concentration below the cut-off point of HBeAg are associated with a greater possibility of obtaining the elimination of HBsAg or seroconversion of HBeAg at least at the end of treatment (Delta for HBsAg clearance OR: 7.27 95% CI: 2.0-26.411 | Absolute concentration for HBeAg seroconversion: adjusted OR (viral load, ALT, age): 10.89 95% CI: 2.63-45.17 ). For HBcrAg, with very low-quality evidence, it cannot be determined whether the decrease in this antigen between weeks 0 and 12 are not associated with the elimination of HBsAg (OR: 2.76 95% CI: 0.85-8.9). Concerning the secondary outcomes, with very low quality of evidence, it cannot be established whether the decrease between weeks 0 and 12 or a concentration below the cut-off point of the three prognostic factors was associated with a viral response or combined. Conclusions: The results of this review show that there is no certainty about the association between the prognostic factors studied here and the response to treatment since the evidence was of very low quality and we cannot concluded that in patients with Chronic Hepatitis B treated with Interferon alfa, the measurement in the blood of the HBsAg concentration at week 12 after starting treatment, can predict the response to treatment when this response is measured as serological, viral or combined. To improve the quality of the evidence, we propose clinical trials in which participants are randomly assigned based on the prognostic factor to modify the treatment or continue with it. Likewise, better multivariate analyses or prognostic studies could be carried out to control confusion better.Incluye anexosMaestríaMagíster en Ciencias Epidemiología Clínicaxx, 137 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Maestría en Epidemiología ClínicaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y saludInterferon-alphaHepatitis BAntigensInterferón-alfaHepatitis BAntígenosHepatitis B CrónicaPronósticoInterferónChronic Hepatitis BPrognosisInterferonChronic Hepatitis BPrognosisInterferonEvaluación de los antígenos virales como factores pronósticos de respuesta al tratamiento con interferón alfa en pacientes con Hepatitis B Crónica: Revisión sistemática y meta análisisEvaluation of viral antigens as prognostic factors of response to treatment with interferon alpha in patients with Chronic Hepatitis B: Systematic review and meta-analysisTrabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TMBireme1. World Health Organization 2017. Global Hepatitis Report 2017. 2017.2. Schmit N, Nayagam S, Thursz MR, Hallett TB. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. Int J Epidemiol. 2021;50(2):560–9.3. OMS | Hepatitis B [Internet]. World Health Organization; [cited 2015 Mar 21]. Available from: http://www.who.int/mediacentre/factsheets/fs204/es/4. Dienstag JL. 46 – Antiviral Drugs against Hepatitis Viruses. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases [Internet]. 2015. p. 563-575.e3. Available from:5. Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: Systematic review and meta-analysis. J Viral Hepat. 2016;23(3):154–69.6. Likhitsup A, Lok AS. Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials. Clin Liver Dis [Internet]. 2019;23(3):401–16. Available from:7. Hu J. Hepatitis B Virus Virology and Replication. In: Hepatitis B Virus in Human Diseases [Internet]. 2016. p. 1–34. Available from: http://link.springer.com/10.1007/978-3-319-22330-8_18. European Association for the Study of the Liver (EASL). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol [Internet]. 2017;67(2):370–98. Available from: http://www.easl.eu/medias/cpg/management-of-hepatitis-B-virus-infection/English-report.pdf9. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis b. J Antimicrob Chemother. 2011;66(12):2715–25.10. Liaw Y-F, Kao J-H, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int [Internet]. 2012;6(3):531–61. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L52014826&from=export11. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.12. Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, et al. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. Can Liver J. 2018;1(4):156–21713. Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, et al. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc [Internet]. 2019;118(1P1):7–38. Available from: https://doi.org/10.1016/j.jfma.2018.11.00814. Ministerio de Salud y Protección Social; Instituto de Evaluación Tecnológica en Salud. Guía de Práctica Clínica Diagnóstico y Tratamiento de Hepatitis B crónica Adopción Sistema General de Seguridad Social en Salud Colombia. 2016;(56):1–287.15. Chan HL-Y, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. J Hepatol [Internet]. 2011;55(5):1121–31. Available from:16. Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol [Internet]. 2019;16(10):631–41. Available from: http://dx.doi.org/10.1038/s41575-019-0197-817. Wu JW, Kao JH, Tseng TC. Three heads are better than two: Hepatitis b core-related antigen as a new predictor of hepatitis b virus-related hepatocellular carcinoma. Clin Mol Hepatol. 2021;27(3).18. Chan HL, Wong VW, Tse AM, Tse C, Chim AM, Chan H, et al. Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. Clin Gastroenterol Hepatol [Internet]. 2007;5(12):1462–8. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L350181604&from=export19. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int [Internet]. 2014 Feb 1 [cited 2015 Jan 27];34 Suppl 1(s1):97–107. Available from: http://aplicacionesbiblioteca.udea.edu.co:2144/doi/10.1111/liv.12403/full20. Mak L-Y, Seto W-K, Fung J, Yuen M-F. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int [Internet]. 2020;14(1):35–46. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2003652617&from=export21. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology. 2009;49(SUPPL. 5).22. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection. Jama [Internet]. 2018;319(17):1802. Available from:23. World Health Organization 2016. GLOBAL HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS 2016-2021 TOWARDS ENDING VIRAL HEPAITITS. 2016;24. Chan HLY, Ahn SH, Chang T-T, Peng C-Y, Wong D, Coffin CS, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J Hepatol [Internet]. 2016;64(5):1011–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L608677780&from=export25. Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Prim [Internet]. 2018;4:1–21. Available from: http://dx.doi.org/10.1038/nrdp.2018.3526. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol. 2003;39(SUPPL. 1):26–30.27. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000 May;15 Suppl:E25-30.28. Wong GLH, Wong VWS, Chan HLY. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis. 2016;62(Suppl 4):S298–305.29. Vlachogiannakos J, Papatheodoridis G V. Optimal therapy of chronic hepatitis B: How do I treat HBeAg-positive patients? Liver Int [Internet]. 2015;35(s1):100–6. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L601030651&from=export30. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 SUPPL. 1).31. Dienstag JL, Delemos AS. 119 – Viral Hepatitis. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases [Internet]. 2015. p. 1439-1468.e7. Available from: http://www.sciencedirect.com/science/article/pii/B978145574801300119332. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012;61(SUPPL. 1).33. Liu C-J, Kao J-H. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013 May;33(2):97–102.34. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000 Jan;81(Pt 1):67–74.35. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000 Mar;118(3):554–9.36. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology [Internet]. 2003 Jan 1;37(1):19–26. Available from: https://doi.org/10.1053/jhep.2003.5003637. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002 Dec;123(6):1848–56.38. Revill PA, Chisari F V., Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545–58.39. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–66.40. Fitzmaurice C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91.41. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J [Internet]. 2016 Jul 14;37(27):2129–200. Available from: http://doi.wiley.com/10.1016/j.ejheart.2008.08.00542. Yang H-I, Lu S-N, Liaw Y-F, You S-L, Sun C-A, Wang L-Y, et al. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. N Engl J Med [Internet]. 2002;347(3):168–74. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa01321543. Lin S-M, Sheen I-S, Chien R-N, Chu C-M, Liaw Y-F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology [Internet]. 1999 Mar;29(3):971–5. Available from: http://doi.wiley.com/10.1002/hep.51029031244. Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol [Internet]. 2013;57(4):323–30. Available from: http://dx.doi.org/10.1016/j.jcv.2013.04.01245. Lauret E, González-Diéguez ML, Rodríguez M, González M, Melón S, Rodrigo L, et al. Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance. Liver Int. 2015;35(1):140–7.46. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—Summary of a workshop. Gastroenterology [Internet]. 2001;120(7):1828–53. Available from: http://linkinghub.elsevier.com/retrieve/pii/S001650850170190447. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of hepatitis B: Summary of a clinical research workshop. Hepatology. 2007;45(4):1056–75.48. Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, et al. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization. Cancer [Internet]. 2007 Oct 15;110(8):1760–7. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cncr.2298449. Konerman MA, Lok AS. Interferon Treatment for Hepatitis B. Clin Liver Dis [Internet]. 2016 Nov;20(4):645–65. Available from: http://dx.doi.org/10.1016/j.cld.2016.06.00250. Samuel CE. Antiviral Actions of Interferons. Clin Microbiol Rev [Internet]. 2001 Oct 1;14(4):778–809. Available from: http://cmr.asm.org/cgi/doi/10.1128/CMR.14.4.778-809.200151. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN- α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. 2012;122(2).52. Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky J-M. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013 Apr;58(4):676–83.53. Wong D, Cheung A, O’Rourke K, Naylor C, Detsky A, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119(4):312–23.54. Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, et al. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol [Internet]. 2018 Mar 28;6(1):1–10. Available from: http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=1&id=10.14218%2FJCTH.2017.0007355. Seo Y. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol [Internet]. 2014;20(37):13284. Available from: http://www.wjgnet.com/1007-9327/full/v20/i37/13284.htm56. Janssen H LA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet [Internet]. 2005 Jan;365(9454):123–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067360517701057. Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, et al. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc [Internet]. 2018;117(7):588–97. Available from: https://doi.org/10.1016/j.jfma.2017.12.00758. Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersöz G, et al. Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007;51(8):3020–2.59. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology [Internet]. 2009 May;49(S5):S103–11. Available from: http://doi.wiley.com/10.1002/hep.2295660. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: Characteristics and vulnerability. J Psychosom Res [Internet]. 2007 Aug;63(2):131–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S002239990700216461. Peng H, Wei F, Liu JY, Hu HD, Ren H, Hu P. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. Hepatol Int. 2015;9(4):543–57.62. Chan HL-Y, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol [Internet]. 2011 Nov 11 [cited 2015 Jan 25];55(5):1121–31. Available from: http://www.journal-of-hepatology.eu/article/S0168827811004971/fulltext63. Lo AO-S, Wong VW-S, Wong GL-H, Chan HL-Y, Dan Y-Y. Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. Clin Gastroenterol Hepatol [Internet]. 2015 Feb [cited 2015 Aug 25];13(2):377-385.e5. Available from: http://www.sciencedirect.com/science/article/pii/S154235651400929X64. Liu T, Zhu G, He J, Song T, Zhang M, Lin H, et al. Early rigorous control interventions can largely reduce dengue outbreak magnitude: Experience from Chaozhou, China. BMC Public Health. 2017;18(1):1–10.65. Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, et al. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virol J [Internet]. 2016;13(1):1–9. Available from: http://dx.doi.org/10.1186/s12985-016-0640-166. Perrillo R, Hou J, Papatheodoridis G, Manns M. Patient management and clinical decision making in HBV - Aims of therapy and what we can achieve. Antivir Ther. 2010;15(SUPPL. 3):45–51.67. Hsu HY, Tsai HY, Wu TC, Chiang CL, Ni YH, Chen PJ, et al. Interferon-α treatment in children and young adults with chronic hepatitis B: A long-term follow-up study in Taiwan. Liver Int. 2008;28(9):1288–97.68. Wiegand J, van Bommel F, Berg T. Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis. 2010;1(212):361–77.69. Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, et al. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2016;44(9):957–66.70. Hadziyannis E, Hadziyannis SJ. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility. Expert Rev Gastroenterol Hepatol [Internet]. 2014;8:185–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2441726471. Chien R-N, Kao J-H, Peng C-Y, Chen C-H, Liu C-J, Huang Y-H, et al. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc [Internet]. 2019;118(1P1):7–38. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2001356312&from=export72. Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. An overview of hepatitis B virus surface antigen secretion inhibitors. Front Microbiol. 2018;9(APR):1–9.73. Ju H, Lai G, Yan F. 6 - Electrochemiluminescent immunosensing. In: Ju H, Lai G, Yan F, editors. Immunosensing for Detection of Protein Biomarkers [Internet]. Elsevier; 2017. p. 171–206. Available from: https://www.sciencedirect.com/science/article/pii/B978008101999300006274. Schnurr B, Ahrens T, Regenass U. Optical assays in drug discovery. Compr Med Chem II. 2006;3:577–98.75. Paul-Ehrlich-Institut. PEI Sero­log­i­cal Ref­er­ence Ma­te­ri­al [Internet]. 2021. Available from: https://www.pei.de/EN/regulation/reference-material/reference-material-node.html76. Karagoz E, Selek MB, Tanoglu A, Hatipoglu M, Ulçay A, Turhan V. Comparison of the Elecsys HBsAg II assay and the Architect assay for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. Infez Med. 2016;24(4):287–92.77. van Halewijn GJ, Geurtsvankessel CH, Klaasse J, van Oord GW, de Knegt RJ, van Campenhout MJ, et al. Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. J Clin Virol [Internet]. 2019;114(February 2019):1–5. Available from: https://doi.org/10.1016/j.jcv.2019.03.00378. Thio CL, Hawkins C. 148 – Hepatitis B Virus and Hepatitis Delta Virus. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases [Internet]. 2015. p. 1815-1839.e7. Available from: http://www.sciencedirect.com/science/article/pii/B978145574801300148X79. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife [Internet]. 2012 Nov 13 [cited 2015 Jan 4];1:e00049. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3485615&tool=pmcentrez&rendertype=abstract80. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology [Internet]. 2015 Mar 7 [cited 2015 Mar 12]; Available from: http://www.sciencedirect.com/science/article/pii/S004268221500077X81. Rodríguez-Frias F, Jardi R. Virología molecular del virus de la hepatitis B. Enferm Infecc Microbiol Clin [Internet]. 2008;26:2–10. Available from: http://dx.doi.org/10.1016/S0213-005X(08)76514-582. Sung JJY, Wong M-L, Bowden S, Liew C-T, Hui AY, Wong VWS, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology [Internet]. 2005;128(7):1890–7. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L40824700&from=export83. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: New trick of old dog. J Gastroenterol. 2013;48(1):13–21.84. Altinbas A, Aktaş B, Basar Ö, Yüksel O, Ekiz F, Yilmaz B, et al. Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection? Ann Hepatol. 2012;11(3):320–5.85. Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology [Internet]. 2009;49(4):1141–50. Available from: http://doi.wiley.com/10.1002/hep.2276086. Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int. 2015;35(5):1540–8.87. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study. J Hepatol. 2009;50(6):1084–92.88. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49(4):1151–7.89. Janssen HLA, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut [Internet]. 2012;61(5):641–5. Available from: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2011-30109690. Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int. 2016;36(6):827–36.91. Nguyen T, Thompson AJ V, Bowden S, Croagh C, Bell S, Desmond P V., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. J Hepatol [Internet]. 2010;52(4):508–13. Available from: http://dx.doi.org/10.1016/j.jhep.2010.01.00792. Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol. 2010;25(9):1498–506.93. Wang M-L, Liao J, Wei B, Zhang D-M, He M, Tao M-C, et al. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy. Infect Dis (Auckl) [Internet]. 2018 Jul 3;50(7):522–30. Available from: https://doi.org/10.1080/23744235.2018.144201894. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364.95. Wilczynski NL, Haynes RB, Eady A, Haynes B, Marks S, McKibbon A, et al. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: An analytic survey. BMC Med. 2004;2:1–5.96. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. PLoS Med. 2014;11(10).97. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427–37.98. Harrer, M., Cuijpers, P., Furukawa, T.A., & Ebert D. Doing Meta-Analysis with R: A Hands-On Guide. 1st ed. Boca Raton, FL: London: Chapmann & Hall/CRC Press; 2021.99. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: Adapting the GRADE framework. Syst Rev [Internet]. 2013;2(1):1. Available from: Systematic Reviews100. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52(2):454–61.101. Chan HLY, Wong VWS, Chim AML, Chan HY, Wong GLH, Sung JJY. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32(11–12):1323–31.102. Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. J Viral Hepat. 2016;23(6):427–38.103. Liaw Y-F, Jia J-D, Chan HLY, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology [Internet]. 2011;54(5):1591–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L51655108&from=export104. Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol [Internet]. 2012;56(5):1006–11. Available from: http://dx.doi.org/10.1016/j.jhep.2011.12.007105. Piratvisuth T, Marcellin P, Popescu M, Kapprell H-P, Rothe V, Lu Z-M. Hepatitis B surface antigen: Association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int [Internet]. 2013;7(2):429–36. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L51491678&from=export106. Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int [Internet]. 2020;14(2):212–24. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2004342428&from=export107. Zhang C, Yang Z, Wang Z, Dou X, Sheng Q, Li Y, et al. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int J Med Sci [Internet]. 2020;17(3):383–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L631162849&from=export108. Marcellin P, Xie Q, Paik SW, Flisiak R, Piratvisuth T, Petersen J, et al. Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS One [Internet]. 2020;15(4). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2005559394&from=export109. Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, et al. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients. World J Gastroenterol. 2015;21(18):5668–76.110. Zhu X, Gong Q, Yu D, Zhang D, Gu L, Han Y, et al. Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. J Clin Virol [Internet]. 2013;57(4):318–22. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L52558617&from=export111. Peng C-Y, Lai H-C, Li Y-F, Su W-P, Chuang P-H, Kao J-T. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther [Internet]. 2012;35(4):458–68. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L51807413&from=export112. Lee I-C, Su C-W, Lan K-H, Wang Y-J, Lee K-C, Lin H-C, et al. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc [Internet]. 2020; Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2010380121&from=export113. Lee IC, Huang YH, Su CW, Wang YJ, Huo TI, Lee KC, et al. CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study. PLoS One. 2013;8(10):1–11.114. Li H, Wang H, Peng C, Zheng X, Liu J, Weng Z, et al. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B. J Huazhong Univ Sci Technol [Medical Sci [Internet]. 2017 Aug 8;37(4):547–55. Available from: http://link.springer.com/10.1007/s11596-017-1771-3115. Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int. 2015;35(5):1540–8.116. Ma H, Yang R-F, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol [Internet]. 2010;25(9):1498–506. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L359429499&from=export117. Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol [Internet]. 2021;74(2):283–92. Available from: https://doi.org/10.1016/j.jhep.2020.08.039118. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-??-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res. 2010;40(3):269–77.119. Zhu M-Y, Chen P-Z, Li J, Yu D-M, Huang D, Zhu X-J, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol [Internet]. 2018 Apr;90(4):721–9. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.25010120. Jia W, Zhu MQ, Qi X, Wang T, Wen X, Chen PD, et al. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J [Internet]. 2019;16(1). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L627530822&from=export121. Boglione L, Cusato J, Cariti G, Di Perri G, D’Avolio A. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. Antiviral Res [Internet]. 2016;136:32–6. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L612977889&from=export122. Gheorghiţǎ VI, Cǎruntu FA, Curescu M, Olaru I, Radu MN, Colţan G, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: A Romanian cohort study. J Gastrointest Liver Dis. 2013;22(1):27–32.123. Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T, Thongsawat S, Sanpajit T, Chonprasertsuk S, et al. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol [Internet]. 2016;31(11):1874–81. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L613365032&from=export124. Chen J, Xu CR, Xi M, Hu WW, Tang ZH, Zang GQ. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels. J Viral Hepat [Internet]. 2017;24(7):573–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L614521674&from=export125. Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience. Clin Ther [Internet]. 2021;43(3):572-581.e3. Available from: https://doi.org/10.1016/j.clinthera.2020.12.022126. Zhu MY, Chen PZ, Li J, Yu DM, Huang D, Zhu XJ, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol. 2018;90(4):721–9.127. Chuaypen N, Posuwan N, Chittmittraprap S, Hirankarn N, Treeprasertsuk S, Tanaka Y, et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon–based therapy. Clin Microbiol Infect [Internet]. 2018;24(3):306.e7-306.e13. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L618234108&from=export128. Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. J Viral Hepat [Internet]. 2016;23(6):427–38. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L606643615&from=export129. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology [Internet]. 2010;52(2):454–61. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L359366376&from=export130. Moucari R, Mackiewicz V, Lada O, Ripault M-P, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology [Internet]. 2009;49(4):1151–7. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L354752655&from=export131. Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int [Internet]. 2015;35(5):1540–8. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L603807797&from=export132. Gheorghiţǎ VI, Cǎruntu FA, Curescu M, Olaru I, Radu MN, Colţan G, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: A Romanian cohort study. J Gastrointest Liver Dis [Internet]. 2013;22(1):27–32. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L368602002&from=export133. Chan HLY, Wong VWS, Chim a. ML, Chan HY, Wong GLH, Sung JJY. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32(11–12):1323–31.134. Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int [Internet]. 2016;36(6):827–36. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L610369463&from=export135. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res [Internet]. 2010;40(3):269–77. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L359134396&from=export136. Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, et al. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virol J [Internet]. 2016;13(1):1–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L612941879&from=export137. Zhu M-Y, Chen P-Z, Li J, Yu D-M, Huang D, Zhu X-J, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol [Internet]. 2018;90(4):721–9. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L620282188&from=export138. Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T, Thongsawat S, Sanpajit T, Chonprasertsuk S, et al. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol. 2016;31(11):1874–81.139. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology [Internet]. 2011;53(3):1054–5. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L361365510&from=export140. Wong GLH, Chan HLY. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69(16):2167–77.141. Inoue T, Tanaka Y. The role of hepatitis B core-related antigen. Genes (Basel). 2019;10(5).142. Mak L-Y, Wong DK-H, Cheung K-S, Seto W-K, Lai C-L, Yuen M-F. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther [Internet]. 2018;47(1):43–54. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L618799527&from=exportPúblico generalORIGINAL1085277852 2021 .pdf1085277852 2021 .pdfTesis de Maestría en Epidemiología Clínicaapplication/pdf4234531https://repositorio.unal.edu.co/bitstream/unal/81060/3/1085277852%202021%20.pdf98928ae75cd540e500327f6018456727MD53LICENSElicense.txtlicense.txttext/plain; charset=utf-84074https://repositorio.unal.edu.co/bitstream/unal/81060/4/license.txt8153f7789df02f0a4c9e079953658ab2MD54THUMBNAIL1085277852 2021 .pdf.jpg1085277852 2021 .pdf.jpgGenerated Thumbnailimage/jpeg6143https://repositorio.unal.edu.co/bitstream/unal/81060/5/1085277852%202021%20.pdf.jpg045623136e4d62c9754f826196aafe8bMD55unal/81060oai:repositorio.unal.edu.co:unal/810602023-08-01 23:04:17.334Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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

Publicaciones similares